TrialInvestigational new drugs2011

Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.

Susanne M Arnold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.